Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• 主要な著者: Jinjin Wang (著者), Ailin Zhao (著者), Hui Zhou (著者), Jinbing Zhu (著者), Ting Niu (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background: Ibrutinib is an oral covalent Bruton's tyrosine kinase inhibitor that has been approved for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia and some other B-cell malignancies. Some studies have found an increased risk of bleeding with ibrutinib. Some studies, however,...